Indeed, in an observational study, O’Caoimh et al. (2014) found a decrease in the rate of cognitive decline in patients with mild to moderate AD receiving BBB-penetrating ACE-Is compared to those on no drug. This evidence concerns the gene ACE and Alzheimer disease.